HCV-related hepatocellular carcinoma: From chronic inflammation to cancer

被引:118
作者
Castello, Giuseppe [1 ]
Scala, Stefania
Palmieri, Giuseppe [3 ]
Curley, Steven A. [4 ]
Izzo, Francesco [2 ]
机构
[1] CROM, Oncol Res Ctr, I-83013 Mercogliano, AV, Italy
[2] Natl Canc Inst Naples, G Pascale Fdn, Hepatobiliary Surg Dept, Naples, Italy
[3] CNR, Ist Chim Biomol, Sassari, Italy
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
关键词
Hepatitis C virus; Hepatocellular carcinoma; Immune response; Inflammation; HEPATITIS-C-VIRUS; REGULATORY T-CELLS; IN-VITRO PROLIFERATION; TOLL-LIKE RECEPTORS; DENDRITIC CELLS; OXIDATIVE STRESS; B-VIRUS; PERIPHERAL-BLOOD; IMMUNE-RESPONSES; CORE PROTEIN;
D O I
10.1016/j.clim.2009.10.007
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Hepatitis C virus (HCV) infection is a worldwide health problem because of its incidence and pathogenicity. It might evolve into chronic disease, cirrhosis, and/or hepatocellular carcinoma (HCC) and the outcome is mainly determined by the host immune response. For viral clearance, combined innate and adaptive immune responses are required; resolution requires a vigorous, durable, polyclonal CD4(+) and CD8(+) T-celt response, with an increase in virus-specific CD8(+) T cells or cytotoxic T lymphocytes. Failure of efficient immune response can lead to chronic inflammation, tissue remodeling through cell growth, apoptosis and/or necrosis and induction of oxidative stress. Development of fibrosis and/or cirrhosis plus a microenvironment conducive to genomic instability mutations will promote neoplastic transformation. System governance derives from cellular (regulatory cells) and humoral (cytokines and chemokines) immune networks. Therefore, HCC pathogenesis may be a model to study the disease progression from chronic inflammation to cancer allowing design of new strategies targeting the immune response, thereby modifying disease outcome. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:237 / 250
页数:14
相关论文
共 157 条
[1]   Subversion of effector CD8+ T cell differentiation in acute hepatitis C virus infection:: the role of the virus [J].
Accapezzato, D ;
Francavilia, V ;
Rawson, P ;
Cerino, A ;
Cividini, A ;
Mondelli, MU ;
Barnaba, V .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2004, 34 (02) :438-446
[2]   Blocking oncogenic Ras signaling for cancer therapy [J].
Adjei, AA .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (14) :1062-1074
[3]  
Aghemo A, 2009, ANTIVIR THER, V14, P577
[4]   Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States From 1975 to 2005 [J].
Altekruse, Sean F. ;
McGlynn, Katherine A. ;
Reichman, Marsha E. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) :1485-1491
[5]   Recovery, persistence, and sequelae in hepatitis C virus infection: A perspective on long-term outcome [J].
Alter, HJ ;
Seeff, LB .
SEMINARS IN LIVER DISEASE, 2000, 20 (01) :17-35
[6]  
*AM CANC SOC, 2007, AG STAND LIV CANC IN, P18
[7]   Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection [J].
Bain, C ;
Fatmi, A ;
Zoulim, F ;
Zarski, JP ;
Trépo, C ;
Inchauspé, G .
GASTROENTEROLOGY, 2001, 120 (02) :512-524
[8]   Immunobiology of dendritic cells [J].
Banchereau, J ;
Briere, F ;
Caux, C ;
Davoust, J ;
Lebecque, S ;
Liu, YT ;
Pulendran, B ;
Palucka, K .
ANNUAL REVIEW OF IMMUNOLOGY, 2000, 18 :767-+
[9]   Dendritic cells and the control of immunity [J].
Banchereau, J ;
Steinman, RM .
NATURE, 1998, 392 (6673) :245-252
[10]   The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection [J].
Barnes, E ;
Harcourt, G ;
Brown, D ;
Lucas, M ;
Phillips, R ;
Dusheiko, G ;
Klenerman, P .
HEPATOLOGY, 2002, 36 (03) :743-754